Kissei Of Japan Licenses Diabetes Drug Rights To GSK
This article was originally published in PharmAsia News
Kissei Pharmaceutical announced June 2 that it signed an agreement with GlaxoSmithKline and granted GSK exclusive development and sales rights to its type 2 diabetes treatment compounds KGT, a group of selective SGLT-2 inhibitors developed by Kissei. The agreement, along with a previous one signed in 2002, grants GSK worldwide rights, including Japan. KGT is at the end of Phase II trials overseas, and it completed Phase I trials in Japan. Focusing on diabetes drug development, Kissei developed Glufast (mitiglinide) and jointly marketed it with Takeda Pharmaceutical in 2004. The GSK agreement will allow Kissei to focus on Glufast's marketing. (Click here for more - Japanese language
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.